![]() ![]() Around 71% of the patients scanned using NETSPOT diagnostic agent found an improvement in their disease management. ![]() ![]() This projection seems to be verified by real life statistics. This gives a solid tool to physicians to detect malignant NET cases in earlier stage of the disease. Since NETSPOT has 100 times higher affinity to somatostatin receptor as compared to Octreoscan, it is expected to result in improved accuracy for NET patients. NETSPOT has managed to demonstrate superior efficacy as compared to the previously approved diagnostic product, Mallinckrodt Pharmaceuticals ( MNK) Octreoscan diagnostic kit by pinpointing 30% more lesions in patients suffering with somatostatin receptor positive NET. There are many reasons why NETSPOT can fast become a preferred choice as a NET diagnostic agent. Oncology, cardiology, and other indications account for around 65%, 33%, and 2%, of the MNM usage, respectively. It is also important to note that these MNDs are used extensively across multiple indications. These statistics highlight the scope of opportunity available for NETSPOT and Advanced Accelerator Applications in the MNM segment. In 2030, global MNM market is expected to be worth $25 billion.Ĭurrently, molecular nuclear diagnostics or MND account for 90% of the total MNM market. Further, in the next 15 years, this segment is expected to rise at a CAGR of 30%, a rate significantly more than that witnessed in other therapeutic segments. Today, the global MNM market, which involves diagnostics and therapeutics, is worth more than $4.0 billion. NETSPOT is a first-in-class drug and was approved by the FDA within record 23 months after the company's first pre-IND meeting with the agency.īefore we take a plunge in understanding the characteristics of NETSPOT, it makes sense to understand the market opportunity available for Advanced Accelerator Applications in MNM segment. Post detection of these NETs, the malignant or benign nature of these tumors is confirmed with histopathology or other methods. Since GA 68 is a positron emitter, it is used in PET scan to locate somatostatin receptor positive NETs in the pancreas, lungs, stomach, and other organs in the body. Food and Drug Administration or FDA approved Advanced Accelerator Applications' NETSPOT, a kit used by the local radiopharmacy to reconstitute an injection, which uses radioactive diagnostic agent, Gallium Ga 68 dotatate. NETSPOT is all set to become a preferred diagnostic drug kit for NET patients I believe that solid ramp up of NETSPOT in USA can prove to be a significant growth opportunity for the company in 2017. In this article, I will present my rationale for considering Advanced Accelerator Applications as a solid buy opportunity in 2017. With Advanced Accelerator Applications launching multiple products across geographies and securing reimbursement, these revenue numbers are expected to rise significantly in 20. ![]() The company reported a compounded average growth rate of 29.5% in its revenues from 2012 to 2015. In 2015, Advanced Accelerator Applications posted revenues close to €88.6 million. The company is also moving closer to launching its first MNM therapy, Lutathera, for neuroendocrine tumor or NET patients both in USA and European Union. This radiopharmaceutical company currently markets seven diagnostic products in the European market and recently launched one of its products in USA.īesides these commercialized diagnostic drug kits, Advanced Accelerator Applications also boasts of six investigational candidates in its research pipeline. Advanced Accelerator Applications offers positron emission tomography or PET and single-photon emission computed tomography or SPECT products which are used to diagnose conditions in areas such as neurology, oncology, cardiology, infectious diseases, and inflammation. Since last few years, the company has been steadily increasing its presence in USA. Advanced Accelerator Applications ( NASDAQ: AAAP) is a leader in the European molecular nuclear medicine or MNM segment. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |